This group has gained an average of 4.2% so far this year, so NVS is performing better in this area. Looking more specifically, Novartis belongs to the Large Cap Pharmaceuticals industry, a group that includes 12 individual stocks and currently sits at #65 in the Zacks Industry Rank. The stock currently has a Zacks Rank #2 (Buy). The stock is up 82% year-to-date.įor Akebia Therapeutics, the consensus EPS estimate for the current year has increased 1.2% over the past three months. One other Medical stock that has outperformed the sector so far this year is Akebia Therapeutics (AKBA). This means that Novartis is performing better than its sector in terms of year-to-date returns. At the same time, Medical stocks have lost an average of 0.5%. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.īased on the latest available data, NVS has gained about 15.4% so far this year. Over the past 90 days, the Zacks Consensus Estimate for NVS' full-year earnings has moved 1.9% higher. Novartis is currently sporting a Zacks Rank of #2 (Buy). NVS holds a better value than 65 of stocks at its current price. Our proprietary scoring system considers the overall health of the company by looking at the stocks price, earnings, and growth rate to determine if it represents a good value. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Novartis AG ( NVS) receives a strong valuation score of 65 from InvestorsObserver analysis. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. Novartis is a member of our Medical group, which includes 1144 different companies and currently sits at #8 in the Zacks Sector Rank.
Has Novartis (NVS) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Stock prices follow Earnings Per Share, which are trending upward. The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. NVS New York Stock Exchange delayed by 15 minutes CURRENCY IN USD Pharmaceuticals.
0 kommentar(er)
